451 related articles for article (PubMed ID: 12124305)
21. Identification of CYP3A7 for glyburide metabolism in human fetal livers.
Shuster DL; Risler LJ; Prasad B; Calamia JC; Voellinger JL; Kelly EJ; Unadkat JD; Hebert MF; Shen DD; Thummel KE; Mao Q
Biochem Pharmacol; 2014 Dec; 92(4):690-700. PubMed ID: 25450675
[TBL] [Abstract][Full Text] [Related]
22. Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety.
Yamaori S; Ebisawa J; Okushima Y; Yamamoto I; Watanabe K
Life Sci; 2011 Apr; 88(15-16):730-6. PubMed ID: 21356216
[TBL] [Abstract][Full Text] [Related]
23. Developmental expression of the major human hepatic CYP3A enzymes.
Stevens JC; Hines RN; Gu C; Koukouritaki SB; Manro JR; Tandler PJ; Zaya MJ
J Pharmacol Exp Ther; 2003 Nov; 307(2):573-82. PubMed ID: 12975492
[TBL] [Abstract][Full Text] [Related]
24. Cytochrome P450 3A expression in the human fetal liver: evidence that CYP3A5 is expressed in only a limited number of fetal livers.
Hakkola J; Raunio H; Purkunen R; Saarikoski S; Vähäkangas K; Pelkonen O; Edwards RJ; Boobis AR; Pasanen M
Biol Neonate; 2001; 80(3):193-201. PubMed ID: 11585982
[TBL] [Abstract][Full Text] [Related]
25. Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro.
Granfors MT; Wang JS; Kajosaari LI; Laitila J; Neuvonen PJ; Backman JT
Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):79-85. PubMed ID: 16433896
[TBL] [Abstract][Full Text] [Related]
26. Expression of CYP3A in the human liver--evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth.
Lacroix D; Sonnier M; Moncion A; Cheron G; Cresteil T
Eur J Biochem; 1997 Jul; 247(2):625-34. PubMed ID: 9266706
[TBL] [Abstract][Full Text] [Related]
27. Metabolism of quetiapine by CYP3A4 and CYP3A5 in presence or absence of cytochrome B5.
Bakken GV; Rudberg I; Christensen H; Molden E; Refsum H; Hermann M
Drug Metab Dispos; 2009 Feb; 37(2):254-8. PubMed ID: 19022943
[TBL] [Abstract][Full Text] [Related]
28. Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs.
McConn DJ; Lin YS; Allen K; Kunze KL; Thummel KE
Drug Metab Dispos; 2004 Oct; 32(10):1083-91. PubMed ID: 15377640
[TBL] [Abstract][Full Text] [Related]
29. The interactions of a selective protein kinase C beta inhibitor with the human cytochromes P450.
Ring BJ; Gillespie JS; Binkley SN; Campanale KM; Wrighton SA
Drug Metab Dispos; 2002 Sep; 30(9):957-61. PubMed ID: 12167559
[TBL] [Abstract][Full Text] [Related]
30. Identification of human liver cytochrome P450 enzymes involved in biotransformation of vicriviroc, a CCR5 receptor antagonist.
Ghosal A; Ramanathan R; Yuan Y; Hapangama N; Chowdhury SK; Kishnani NS; Alton KB
Drug Metab Dispos; 2007 Dec; 35(12):2186-95. PubMed ID: 17827338
[TBL] [Abstract][Full Text] [Related]
31. Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes.
Lalovic B; Phillips B; Risler LL; Howald W; Shen DD
Drug Metab Dispos; 2004 Apr; 32(4):447-54. PubMed ID: 15039299
[TBL] [Abstract][Full Text] [Related]
32. Stereoselective metabolism of endosulfan by human liver microsomes and human cytochrome P450 isoforms.
Lee HK; Moon JK; Chang CH; Choi H; Park HW; Park BS; Lee HS; Hwang EC; Lee YD; Liu KH; Kim JH
Drug Metab Dispos; 2006 Jul; 34(7):1090-5. PubMed ID: 16581944
[TBL] [Abstract][Full Text] [Related]
33. Ethnic differences between Japanese and Caucasians in the expression levels of mRNAs for CYP3A4, CYP3A5 and CYP3A7: lack of co-regulation of the expression of CYP3A in Japanese livers.
Yamaori S; Yamazaki H; Iwano S; Kiyotani K; Matsumura K; Saito T; Parkinson A; Nakagawa K; Kamataki T
Xenobiotica; 2005 Jan; 35(1):69-83. PubMed ID: 15788369
[TBL] [Abstract][Full Text] [Related]
34. Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus.
Kamdem LK; Streit F; Zanger UM; Brockmöller J; Oellerich M; Armstrong VW; Wojnowski L
Clin Chem; 2005 Aug; 51(8):1374-81. PubMed ID: 15951320
[TBL] [Abstract][Full Text] [Related]
35. No ethnic difference between Caucasian and Japanese hepatic samples in the expression frequency of CYP3A5 and CYP3A7 proteins.
Tateishi T; Watanabe M; Moriya H; Yamaguchi S; Sato T; Kobayashi S
Biochem Pharmacol; 1999 Apr; 57(8):935-9. PubMed ID: 10086328
[TBL] [Abstract][Full Text] [Related]
36. Cytochrome P450 3A-dependent metabolism of a potent and selective gamma-aminobutyric acid Aalpha2/3 receptor agonist in vitro: involvement of cytochrome P450 3A5 displaying biphasic kinetics.
Ma B; Polsky-Fisher SL; Vickers S; Cui D; Rodrigues AD
Drug Metab Dispos; 2007 Aug; 35(8):1301-7. PubMed ID: 17460031
[TBL] [Abstract][Full Text] [Related]
37. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450.
Rehmel JL; Eckstein JA; Farid NA; Heim JB; Kasper SC; Kurihara A; Wrighton SA; Ring BJ
Drug Metab Dispos; 2006 Apr; 34(4):600-7. PubMed ID: 16415119
[TBL] [Abstract][Full Text] [Related]
38. Ethanol inhibits in-vitro metabolism of nifedipine, triazolam and testosterone in human liver microsomes.
Patki KC; Greenblatt DJ; von Moltke LL
J Pharm Pharmacol; 2004 Aug; 56(8):963-6. PubMed ID: 15285839
[TBL] [Abstract][Full Text] [Related]
39. Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs.
Walsky RL; Obach RS; Hyland R; Kang P; Zhou S; West M; Geoghegan KF; Helal CJ; Walker GS; Goosen TC; Zientek MA
Drug Metab Dispos; 2012 Sep; 40(9):1686-97. PubMed ID: 22645092
[TBL] [Abstract][Full Text] [Related]
40. Characterization of CYP3A isozymes involved in the metabolism of domperidone: role of cytochrome b5 and inhibition by ketoconazole.
Michaud V; Simard C; Turgeon J
Drug Metab Lett; 2010 Apr; 4(2):95-103. PubMed ID: 21281268
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]